SCHEMBL5244961

SCHEMBL5244961

O=C(O)C1CCCN(S(=O)(=O)c2ccc(Cl)s2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 1.00
▸ L3MBTL1 Q9Y468 2/20 1.00
▸ MMP8 P22894 1/20 0.63
▸ MMP12 P39900 1/20 0.63
▸ MMP13 P45452 1/20 0.63
▸ ALDH1A1 P00352 3/20 0.58
▸ MAPT P10636 1/20 0.56
▸ AKR1C3 P42330 6/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ LMNA P02545 2/20 0.55
▸ AKR1C1 Q04828 2/20 0.55
▸ HTT P42858 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ POLB P06746 1/20 0.53
▸ TP53 P04637 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25989026 0.86 L3MBTL1 (0.76) TSHRL3MBTL1MMP8MMP12MMP13
SCHEMBL29023287 0.85 L3MBTL1 (0.74) TSHRL3MBTL1MMP8MMP12MMP13
Lithium SCHEMBL30471801 0.85 L3MBTL1 (0.74) TSHRL3MBTL1MMP8MMP12MMP13
SCHEMBL5245574 0.84 POLB (0.74) TSHRL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL5244127 0.78 MEN1 (0.72) TSHRL3MBTL1ALDH1A1SMN1; SMN2HTT
SCHEMBL5243826 0.78 MEN1 (0.72) TSHRL3MBTL1ALDH1A1SMN1; SMN2HTT
SCHEMBL5282637 0.78 MEN1 (0.72) TSHRL3MBTL1ALDH1A1SMN1; SMN2HTT
SCHEMBL894072 0.77 MMP8 (1.00) TSHRL3MBTL1MMP8MMP12MMP13
SCHEMBL894074 0.77 MMP8 (1.00) TSHRL3MBTL1MMP8MMP12MMP13
SCHEMBL5244762 0.77 MAPT (0.76) TSHRL3MBTL1ALDH1A1MAPTAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866285-A1 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. Hoffmann-Roche AG (CH) 2007-12-19 — — EP claimed
WO-2006094633-A1 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. HOFFMAN-LA ROCHE AG (CH) 2006-09-14 — — WO claimed
EP-1866285-A1 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. Hoffmann-Roche AG (CH) 2007-12-19 — — EP disclosed
WO-2006094633-A1 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. HOFFMAN-LA ROCHE AG (CH) 2006-09-14 — — WO disclosed
US-20060199816-A1 Aryl sulfonyl piperidines GILLESPIE PAUL 2006-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199816-A1 Aryl sulfonyl piperidines GPR119, SLC5A2, GLS2 TSHR 761/4885L3MBTL1 4638/4885MMP8 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback